Most important take away

Grammy-nominated singer-songwriter Aloe Blacc is bootstrapping a biotech company (Pepto ID, under holding company Major Inq) targeting pancreatic cancer using a novel molecule-discovery platform from University of Houston chemist Dr. Golnica Udugamasuriya. He is deliberately waiting on peer-reviewed papers before tapping his network for dilutive capital, and is pursuing non-dilutive government and foundation funding in the meantime — a reminder that in biotech, scientific validation is the single biggest unlock for fundraising leverage.

Summary

Actionable insights

• Invest in leaders, not just ideas. Blacc’s earliest startup investing lesson: “you’re investing in the leadership of the startup.” Great ideas fail when the founder is the wrong operator. If you’re writing checks, diligence the person as hard as the pitch — or be prepared to step in as operator yourself (as Blacc eventually did with Major Inq/Pepto ID).
• In biotech, wait for peer-reviewed papers before calling your network. Blacc explicitly says his name carries no weight in biotech circles, so he’s holding off on angel rounds until published papers can do the validating for him. Lesson: when raising outside your domain, let third-party credibility (papers, benchmarks, design partners) speak before you spend social capital.
• Prefer deep pockets over shallow ones, even if it means waiting. Blacc is passing on available angel money because the capital needs of biotech (~10 years, hundreds of millions) demand investors who can follow on. Pattern-match this to any capital-intensive business: an early shallow round can anchor your cap table to the wrong partners.
• Bootstrap with non-dilutive funding where the ecosystem supports it. Pepto ID is tapping Texas/University of Houston’s cancer research ecosystem and government grants before taking equity dollars. For deep-tech founders, mapping state and federal non-dilutive programs (SBIR, CPRIT in Texas, private disease foundations) can extend runway without dilution.
• Use AI tools as prototyping, not production. Blacc uses Suno to turn 25 years of voice memos into fully produced demos he then re-records with his live band at studio fidelity. The analog to software: “vibe coding” for prototypes, human craftsmanship for the shipped product. AI accelerates the journey; it doesn’t replace the final build.
• Retain copyright by keeping humans in the loop. The US Copyright Office has ruled AI-generated art is not copyrightable. Blacc’s workaround: use AI to ideate, then create the final output yourself so you retain ownership. This is a real legal/IP playbook for any creator or founder using generative tools.
• If you license your voice/likeness to AI, negotiate oversight and payment structure. Blacc would license his voice but only with content/messaging oversight and a negotiated payment structure. Anyone with an audience asset should think about the same terms before signing.
• Pandemics, not merit, accelerate regulatory pipelines. mRNA was designed for cancer but only reached humans via COVID. The actionable read: in regulated industries, identify the adjacent emergency or comorbidity that can pull your technology through approval faster.
• Purpose > pure speed. Blacc’s closing point: AI compresses the journey, but the journey is where purpose lives. For founders, don’t automate away the parts of the work that give it meaning — and don’t assume speed alone wins if your competitor is also using the same tools.

Stocks and investments mentioned

• Major Inq — Blacc’s holding company, originally formed to license IP from the University of Houston for COVID-era research. Pivoted toward oncology.
• Pepto ID — The operating biotech subsidiary, focused on pancreatic cancer using Dr. Udugamasuriya’s molecule-discovery platform. Not currently fundraising externally; bootstrapped with Blacc’s own capital plus non-dilutive government/foundation money. Not investable today — watch for peer-reviewed publications as the trigger for a priced round.
• Apple Music and Spotify — Named as the dominant streaming incumbents capturing the lion’s share of streaming revenue; Blacc notes major labels own significant equity in streaming platforms, which he frames as a structural lock on the music economy. Not a buy/sell call, but a reminder that streaming economics are shaped by label-platform equity entanglement.
• Suno — The AI music tool Blacc uses most, citing best UI and fastest response. Private company; no direct public investment vehicle, but notable as the category leader for founders tracking generative audio.
• Dr. Udugamasuriya’s platform (University of Houston) — 10 patents, claims to cut 5 years and millions off standard drug discovery by producing hundreds of thousands of physical (not just in-silico) molecules and screening them against biomarkers with a color-coded binding assay. This is the underlying scientific asset any future Pepto ID investment would be backing.

Career advice highlighted

• Find your purpose and engage it — don’t outsource the whole journey to AI or you lose the reason to do the work.
• If you’re an indie artist today, business savvy is the real moat: storytelling, audience building, and physical-world presence are what AI can’t replicate.
• Incumbency matters: Blacc credits his pre-AI catalog and audience for letting him avoid direct competition with AI-generated artists. For anyone building a personal brand, start the flywheel now.
• Be willing to step from investor into operator when a mission requires it — philanthropy alone isn’t enough in capital-intensive fields.

Chapter Summaries

1. Intro and guest setup

Rebecca Bellan introduces Aloe Blacc — Grammy-nominated singer-songwriter (“I Need a Dollar,” co-writer of Avicii’s “Wake Me Up”) — as a biotech founder, framing the episode around AI reshaping creative industries and creators acting like investors.

2. From philanthropy to operator

Blacc explains he initially tried to fund biotech as philanthropy but learned the industry’s cash intensity required him to step in as operator. He partnered with Dr. Golnica Udugamasuriya at the University of Houston, a biological chemist whose platform produces molecules that bind any biomarker structure — not just proteins — broadening disease-targeting options.

3. Investing lessons and why leaders matter

Blacc recounts earlier startup investments that failed because founders with great ideas weren’t great operators. Key takeaway: you invest in the leader, not just the idea. Biotech’s stakes — a “double bottom line” of profit and lives saved — raised the bar.

4. COVID origins and the Major Inq / Pepto ID structure

COVID motivated Blacc to fund preventative research. Major Inq was formed to license the university’s IP; Pepto ID was spun out to focus on oncology (pancreatic cancer), with Major Inq acting as holding company. He notes mRNA was originally designed for cancer but only reached humans via COVID — pandemics bulldoze regulatory pipelines in ways science alone can’t.

5. The hard part of biotech

Blacc enumerates biotech’s stacked headwinds: bench failure, regulatory failure, clinical failure in humans, and then competition post-approval. Timelines of 10+ years and hundreds of millions of dollars. He’s bootstrapping, pursuing non-dilutive government funding, and deliberately waiting for peer-reviewed publications before approaching his network — his celebrity doesn’t carry weight among biotech investors, so the papers have to do the talking. He’s also holding out for deep-pocketed investors over available angel capital.

6. The science: cutting 5 years off drug discovery

Dr. Udugamasuriya’s process combines in-silico design with physical production of hundreds of thousands of molecules and a color-coded binding assay. He has 10 patents and “three for three” successes. Blacc claims this collapses years and millions out of typical drug discovery workflows. FDA pipeline steps (animals, then humans) still can’t be accelerated, and shouldn’t be.

7. AI and the creative industries: copyright, leverage, replaceability

Shift to music. The US Copyright Office has ruled AI-generated art not copyrightable, so savvy creators use AI to ideate but create the final work themselves to preserve copyright. For indie artists, AI is both a leverage tool and a replacement threat — business savvy and audience-building are the differentiators AI can’t match. Blacc cites K-pop Demon Hunters as evidence audiences will accept non-human “artists.”

8. Licensing voices and who benefits economically

Blacc would license his voice with content oversight and the right payment structure, and believes anyone whose work trains a model should be compensated. He predicts major labels will ultimately benefit most from AI music because of their equity stakes in streaming platforms — “same old people finding new ways to squeeze.” He describes it as extortion. He sees a future where AI production tools become streaming platforms themselves.

9. How Blacc actually uses AI in his workflow

He uses Suno to turn decades of voice memos into fully produced demos, then re-records them with his six-piece band at studio fidelity. In five days of studio time with six musicians, they cut 12 songs; Suno could prototype 100 in the same window. AI is a prototyping layer — the final product still goes through the band. He draws a parallel to “vibe coding” in enterprise software: good for prototypes, humans still build production.

10. Closing thoughts on purpose and AI

Blacc’s closing philosophy: humanity is about purpose, and AI compressing the journey also compresses the meaning. Competitive pressure forces adoption, but the fun of building is in the journey itself. Listeners directed to aloeblacc.com.